Arthritis News and Research

Latest Arthritis News and Research

Positive data from Augurex's RA biomarker blood test, novel drug target presented at EULAR conference

Augurex Life Sciences Corp. today reported that in London at the European League Against Rheumatism Conference, leading arthritis researchers presented important data on Augurex's rheumatoid arthritis biomarker blood test and novel drug target.

30 May 2011

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

UCB today announced data which showed that the addition of Cimzia to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients.

30 May 2011

Study: Cardiovascular disease may be under treated in rheumatoid arthritis patients

Results of a study, involving 98,454 patients demonstrated that at 30 days following their first heart attack, RA patients were approximately 20% less likely to be prescribed standard MI treatments, such as statins and betablockers, compared to healthy patients.

27 May 2011

Adalimumab plus methotrexate helps achieve higher levels of disease control in early RA

Data presented today at the EULAR 2011 Annual Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus methotrexate in early RA patients can provide high levels of disease control in many patients, and may also offer the opportunity to change future treatment options for some.

27 May 2011

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune and cancer diseases, will present pre-clinical data on vidofludimus - its lead small-molecule drug candidate against autoimmune diseases - in systemic lupus erythematosus at EULAR 2011, Europe's largest scientific conference on rheumatic diseases, in London, UK, from May 25-28, 2011.

27 May 2011

Positive results from CEL-SCI's LEAPS H1N1-activated dendritic cells trial in mice

CEL-SCI Corporation today announced the positive results of efficacy studies in mice of L.E.A.P.S.TM H1N1 activated dendritic cells to treat the H1N1 virus.

27 May 2011

Gout drug success for Novartis

Novartis AG's new gout therapy drug gives patients better pain relief and significantly cuts the risk of new attacks say two late stage studies. The studies show that more than 450 patients taking Ilaris, or ACZ885, had less pain and the risk of new attacks were reduced by up to 68 percent compared to those taking an injectable steroid to treat gouty arthritis attacks, which can last for a week or more.

26 May 2011

Specific influenza immunization strategies for RA patients may be required for future flu pandemics

A Brazilian hospital-based study assessed responses to flu vaccines in 340 RA patients in regular follow-up compared to 234 healthy patients.

26 May 2011

HPV vaccination does not affect rate of disease flares in patients with SLE, study finds

Results of a Chinese study showed that the HPV vaccine did not have significant effects on the number of disease flares or antibody measures in patients with inactive SLE receiving stable doses of medications after administration, and therefore was determined safe to use to prevent HPV in this group of patients.

26 May 2011

Yoga improves quality of life in patients with fibromyalgia, rheumatoid arthritis

Individuals with rheumatoid arthritis who practice yoga showed statistically significant improvements in disease activity, according to a small study presented at the EULAR 2011 Annual Congress.

26 May 2011

Patients with rheumatoid arthritis two times more likely to have concurrent COPD

Patients with rheumatoid arthritis are two times more likely to have concurrent chronic obstructive pulmonary disease than healthy controls -- an association which was sustained even when variables such as age, gender, smoking and obesity were controlled for, according to a study presented today at the EULAR 2011 Annual Congress.

26 May 2011

Tofacitinib safe and effective for patients with rheumatoid arthritis

Results of a Phase III study presented today at the EULAR 2011 Annual Congress show that at 6 months, 58.3 percent of patients who had previously not responded to treatment with DMARDs, achieved ACR20 response when treated with the novel oral Janus kinase inhibitor tofacitinib at 10mg BID compared to 31.2 percent in the placebo group. Significant improvements were also observed in the 5 mg BID dose.

26 May 2011

Impact of gaming devices on finger and wrist pain in children presented at EULAR 2011

For the first time, results on the impact of gaming devices on finger and wrist pain in children were presented today at the EULAR 2011 Annual Congress. Data comparing two schools in the USA demonstrate that young children experience high levels of pain following long term use of gaming devices and mobile phones indicating that excessive gaming may negatively impact on joint health.

26 May 2011

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Ardea Biosciences, Inc. announced that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, UK.

26 May 2011

Scientists discover new mechanism that controls inflammation

The molecular machines that defend our body against infection don't huff and puff, but some of them apparently operate on the same principle as a steam engine.

26 May 2011

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings to be presented from pooled analyses of the STELARA psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.

25 May 2011

Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011

Novartis announced results of two pivotal Phase III trials in patients with severe gouty arthritis, showing that ACZ885 provided superior pain relief and reduced the risk of suffering new attacks by up to 68% compared to an injectable steroid used to treat gouty arthritis attacks.

25 May 2011

Leukemia protein plays a role in Alzheimer's disease

After decades of studying the pathological process that wipes out large volumes of memory, scientists at The Feinstein Institute for Medical Research discovered a molecule called c-Abl that has a known role in leukemia also has a hand in Alzheimer's disease.

25 May 2011

Vectra DA blood test may help predict patients' response to rheumatoid arthritis therapy

Crescendo Bioscience- today announced data indicating that Vectra- DA, a first-in-class multi-biomarker blood test used to assess rheumatoid arthritis disease activity, provides physicians with an objective measure which may help determine whether patients are responding to therapy.

25 May 2011

Tumor necrosis factor can suppress inflammation, treat rheumatoid arthritis

A new study by rheumatologists at Hospital for Special Surgery in New York has shown that a powerful pro-inflammatory protein, tumor necrosis factor, can also suppress aspects of inflammation.

23 May 2011

Arthritis News and Research

Latest Arthritis News and Research

Positive data from Augurex's RA biomarker blood test, novel drug target presented at EULAR conference

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

Study: Cardiovascular disease may be under treated in rheumatoid arthritis patients

Adalimumab plus methotrexate helps achieve higher levels of disease control in early RA

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

Positive results from CEL-SCI's LEAPS H1N1-activated dendritic cells trial in mice

Gout drug success for Novartis

Specific influenza immunization strategies for RA patients may be required for future flu pandemics

HPV vaccination does not affect rate of disease flares in patients with SLE, study finds

Yoga improves quality of life in patients with fibromyalgia, rheumatoid arthritis

Patients with rheumatoid arthritis two times more likely to have concurrent COPD

Tofacitinib safe and effective for patients with rheumatoid arthritis

Impact of gaming devices on finger and wrist pain in children presented at EULAR 2011

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Scientists discover new mechanism that controls inflammation

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011

Leukemia protein plays a role in Alzheimer's disease

Vectra DA blood test may help predict patients' response to rheumatoid arthritis therapy

Tumor necrosis factor can suppress inflammation, treat rheumatoid arthritis

Pharmaceutical Manufacturing - Industry Focus eBook eBook

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Arthritis News and Research

Latest Arthritis News and Research

Pharmaceutical Manufacturing - Industry Focus eBook eBook

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Newsletters you may be interested in